GLP-1 Receptor Agonists (like Semaglutide, Wegovy, Mounjaro) need to be studied more to be considered "Safe to Recommend"
Why?
The longest study available is 7 years long:
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
https://dovepress.com/long-term-management-of-type-2-diabetes-with-glucagon-like-peptide-1-r-peer-reviewed-fulltext-article-DMSO
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
https://dovepress.com/long-term-management-of-type-2-diabetes-with-glucagon-like-peptide-1-r-peer-reviewed-fulltext-article-DMSO
And it proved these side/adverse effects so far:
Nausea: Frequently reported across all GLP-1RAs, with incidence rates varying from 10.3% for albiglutide to up to 43.5% for lixisenatide.
Diarrhea: Another common side effect, with rates ranging from 12.6% for albiglutide to 16.5% for liraglutide.
Vomiting: Reported particularly with dulaglutide (8%-14%) and lixisenatide (7.2%-18.0%).
Upper Respiratory Tract Infections: Mentioned as a common adverse event, notably in studies with albiglutide (16.2%) and exenatide QW (41.9%).
Injection-site Reactions: Noted with several GLP-1RAs, including albiglutide (9.6%) and exenatide QW, where there was a decrease in injection-site pruritus over time.
Who funded the longest study?
Big Pharma: AstraZeneca
How do I know Big Pharma (AstraZeneca) funded it?
The document explicitly states that medical writing support was provided by Richard Ogilvy-Stewart, PhD, of Mudskipper Business Limited, which was funded by AstraZeneca, United Kingdom.
And another one of the authors, Ravi Jandhyala, is mentioned as being a Consultant Pharmaceutical Physician contracted with AstraZeneca during the development of the manuscript.
These acknowledgments within the document confirm AstraZeneca's involvement in funding and supporting the study.
And another one of the authors, Ravi Jandhyala, is mentioned as being a Consultant Pharmaceutical Physician contracted with AstraZeneca during the development of the manuscript.
These acknowledgments within the document confirm AstraZeneca's involvement in funding and supporting the study.
Does AstraZeneca produce GLP-1 Receptor Agonists?
Yes, they do = Exenatide
Exenatide, which was one of the GLP-1RAs discussed in the study.
Exenatide is marketed under the brand names Byetta (twice daily) and Bydureon (once weekly).
Exenatide, which was one of the GLP-1RAs discussed in the study.
Exenatide is marketed under the brand names Byetta (twice daily) and Bydureon (once weekly).
We have not properly studied this drug with a true 3rd Party study.
Our current studies are funded by the manufacturers of the drug.
That's called a conflict of interest.
We should tread carefully when taking recommendations from science that is funded by Big Pharma companies like:
AstraZeneca who makes Exenatide (Byetta, Bydureon)
NovoNordisk who makes Semaglutide (Ozempic, Wegovy)
Elli Lilly who makes: Dulaglutide (Trulicity), Tirzepatide (Mounjaro, Zepbound)
NovoNordisk who makes Semaglutide (Ozempic, Wegovy)
Elli Lilly who makes: Dulaglutide (Trulicity), Tirzepatide (Mounjaro, Zepbound)
How can we know if these studies that are funded by the makers of the drug are reporting adverse effects properly?
Is it likely that they would belittle adverse effects and embellish positive outcomes if it means they could sell more of their GLP-1 Receptor Agonistss to us?
Is it likely that if they make enough biased studies like this, they will have enough "science" for government to endorse it as a treatment for adults, and then our children?
Furthermore, outside of studies, there is anecdotal testimonies emerging on YouTube and X that show when the dose hits a certain threshold, many people cite loss of desire, such as not wanting to eat their favorite foods anymore, not liking their favorite activities, not enjoying pleasure as much.
The bottom line is, GLP-1 Receptor Agonists are not nearly studied enough to call them safe; we need more independent studies.
Follow for more on health, healthcare, politics:
https://x.com/Room2ImproveX
For more information on GLP-1 Receptor Agonistss, @BenBickmanphD is a great resource:
https://x.com/BenBikmanPhD/status/1866878204402897092